eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
Share:
Share:
more
 
 
Basic research

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development

Yoon Young Kim
,
Woo Oh Kim
,
Hung Ching Liu
,
Zev Rosenwaks
,
Jae Won Kim
,
Seung-Yup Ku

Online publish date: 2019/01/30
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

The survival rate of women with a variety of cancers has increased significantly with improvements in cancer treatment, including early detection and effective management [1]. An increasing number of reproductive-age female cancer survivors require quality-of-life care, covering the preservation of their fecundity, from clinicians and healthcare professionals.
Female reproductive function is represented by cyclic ovarian follicular development. Ovarian follicles are composed of oocytes and granulosa cells (G-cells), which are germ and somatic cells, respectively [2]. Although this machinery should work together in order to achieve physiological follicular development and oocyte maturation, different chemotherapeutic agents with different mechanisms of action may affect each component cell in a different way.
Cisplatin and paclitaxel are the most widely used chemotherapeutic agents for the treatment of gynaecological malignancies, and their mechanisms of action against ovarian cancer cells have been thoroughly investigated. Cisplatin interferes with DNA replication, which kills the fastest proliferating cells [3]. Paclitaxel’s mechanism of action involves the interference with the normal breakdown of microtubules during cell division [3]. Paclitaxel acts as a mitotic inhibitor by disrupting microtubule function [4] and is able to alter mitochondrial membrane permeability in vitro [5].
Some recent studies have focused on the effects of their in vivo administration that caused primordial follicular apoptosis observed from a cross-section of the whole ovarian tissue [3]. However, the magnitude of reproductive toxicological potential affecting normal ovarian follicular development is still unknown. This issue is critical in that clinicians can cite these data, if available, during pre-chemotherapy counselling sessions with reproductive-age cancer patients, in regard to the expected decrease in their future reproductive potential. It is also important from the perspective that the efficacy of in vitro follicular culture can be assumed using cryopreserved ovarian tissue collected after the initiation of chemotherapy.
This study aimed to investigate the concentrations at which cisplatin and paclitaxel affect the in vitro development of ovarian follicles. The effects of each agent alone or their combination on the follicular growth pattern were studied. In addition, whether these effects differentially affect the oocytes and surrounding granulosa cells was also evaluated.

Material and methods

Ethics

All of the experimental procedures in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University Hospital (#15-0016-S1A0).

In vitro follicular development

Thirteen-day-old C57BL/6 mice were sacrificed [6–10], and each ovary was isolated as previously reported. Collected ovaries were dissociated mechanically and single follicles larger than 100 µm diameter were selected and grown in a single droplet of each media. Half of the volume of medium was changed every 2 days until day 13. On day 13, human chorionic gonadotropin (hCG, Ovidrel®, Merck Serono) at 100 mIU and epidermal growth factor (EGF, Invitrogen) at 10 ng/ml were added to induce the extrusion of cumulus-oocyte complex (COC). Grown follicle was classified as healthy and well-grown if the follicles remained normal in structure, with close contact between oocyte and the surrounding granulosa cells (G-cells), and as degenerated follicles if the oocyte and G-cells were not visible under microscopic observation.

Measurement of follicular diameter, survival, ovulation, and maturation rates

The diameters of growing follicles were measured between the poles of extreme theca cells using i-solution program (i-solution, Daejeon, Korea), and the average of each follicle was calculated. Survival of each follicle was calculated by counting the follicles expanded in vitro after seeding. After 36 h of hCG and EGF treatments, the number of ovulated COCs containing healthy oocyte at the stage of metaphase I (MI) or metaphase II (MII) was observed.

Preparation of culture medium and treatment with chemotherapeutic agents

Preparation of culture media was performed as reported previously. Briefly, MEM alpha (Invitrogen, CA, USA) was used as basal medium. Medium was supplemented with 5% foetal bovine serum (FBS, HyClone, Logan, UT, USA), 10 mM penicillin-streptomycin (Invitrogen), and 1 mM insulin-transferrin-selenium (ITS, Invitrogen). In addition, culture media was supplemented with 200 mIU/ml of recombinant human FSH (Gonal-F®, Merck Serono) and 100 mIU/ml of LH (Luveris®, Merck Serono). Finally, 25 µl of media was seeded as droplets on a culture dish and covered with mineral oil (Sigma-Aldrich, St. Louis, MO, USA).
Stock solutions of cisplatin (Sigma-Aldrich) were prepared using 0.5 M NaCl (Sigma-Aldrich), and Paclitaxel (Sigma-Aldrich) was prepared at a concentration of 1 × 10–3 M. Final concentrations in the culture medium were 10–8, 10–9, and 10–10 M. In the experimental group, follicles were cultured in each group of medium containing cisplatin (C), paclitaxel (P), and cisplatin with paclitaxel (C + P).

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

Total RNA was extracted from ovarian follicles using Trizol (Invitrogen). cDNA was synthesised from 0.5 µg of total RNA and using Accute premix (Bioneer, Daejeon, Korea). Each specific primer set was added to the cDNA, and the reactions were amplified under the following conditions: incubation for 10 min at 95°C, denaturation for 20 s at 95°C, annealing for 50 s at 58°C and 30 s for 72°C for extension. All the reactions were carried out in triplicate and the expression of Ct was calculated based on the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression (Table I).

Immunostaining analysis

Follicles of each group were washed with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich) for 20 min at room temperature. They were incubated with bovine serum albumin (BSA, Sigma-Aldrich) blocking solution at 4°C overnight.
Primary antibody, rabbit anti-mouse X-linked inhibitor of apoptosis protein (XIAP) (Abcam, Cambridge, UK), was treated at 4C overnight and washed three times with PBST (PBS containing Triton X-100, Sigma-Aldrich). Secondary antibody, goat anti-rabbit IgG 488 (Molecular Probes, CA, USA) was added and incubated for 30 min at 37°C and washed three times with PBST. For the staining of the nucleus, 10 µM of DAPI was added and samples were observed under a fluorescence microscope (EVOS-FL, Life Technologies, USA).

Transmission electron microscope (TEM) analysis

Dissected follicles were washed with PBS and then fixed with 2.5% glutaraldehyde (Sigma-Aldrich). Samples were fixed with 2% aqueous OsO4 (Sigma-Aldrich) and serially dehydrated. Then, dehydrated samples were embedded, sectioned, and observed using JE-1000 (Japan).

Statistical analysis

All statistical analyses were performed using the Statistical Package for Social Science 21.0 (SPSS Inc., Chicago, IL, USA). The data were analysed with the Student t-test. Differences were considered statistically significant when p < 0.05.

Results

Determination of treated chemo-reagent concentrations

The concentration range of each reagent between 10–8 M and 10–10 M was tested. To determine the treatment concentrations, those were selected that led to the apoptosis of in vitro grown follicles, not a lethal dose of cell death during in vitro development of isolated, pre-antral follicles. 10–10 M of each reagent was decided as the treatment concentration (Figure 1).

Effects of chemo-reagents on in vitro follicle development and oocyte maturation

The control group showed in vitro matured and ovulated normal oocytes after hCG treatment. To evaluate the effects of chemo-reagents, 10–10 M of cisplatin and paclitaxel, alone or in combination, were treated to the in vitro growing day 5 follicles for 5 days. The expansion degree of each follicle of treated groups was significantly decreased compared to controls and the follicles gradually degenerated. Ovulation was not observed in all the treated groups (Figure 2 A, Supplementary Figure 1).
The survival rates were further decreased in the combination group compared to single agent groups (Figure 2 B). Most of the treated groups showed abnormal morphology such as shrinkage of follicles and extrusion of oocytes (Figure 3), while the control group showed ovulated mature oocytes. Degeneration of follicles and oocytes was more remarkable in the combined group than in single agent groups.

Expression of apoptosis- and development-related genes and localisation of XIAP

The expression of anti-apoptosis genes in the G-cells, Bcl2, and XIAP, was significantly down-regulated by the treatment with chemo-reagents, either alone or in combination. The expression of oocyte development-related genes, growth differentiation factor 9 (GDF9), and bone morphogenetic protein 15 (BMP15) was also down-regulated. Combined treatment culminated in further suppression of the expression of all evaluated genes (Figure 4). The expression of XIAP protein was observed in the cytoplasm of G-cells. Its expression was decreased in all treated groups (Figure 5).

Ultra-structural analysis of chemo-reagent treated follicles

When the ultra-structure of G-cells was analysed, control groups showed evenly distributed cells around oocyte. In contrast, the treated groups showed various sizes, morphologies, and uneven distributions of G-cells. They had the accumulation of metabolic waste such as lipid droplets and degenerated or non-expanded mitochondria (Figure 6).

Discussion

This study showed differential effects of cisplatin and paclitaxel on in vitro follicular growth, in terms of oocyte and follicular cells. The observed effects were significantly different between oocytes and G-cells regarding their gene expression and morphological alteration. To our knowledge, this is among the first studies to evaluate the effects of cisplatin and paclitaxel on in vitro developing murine follicles using a previously settled system by our group [6, 7, 11].
Along with the increased survival after chemotherapy of cancer patients, fertility preservation in female patients became a rising issue in the gynaecological oncology field [12]. Chemotherapy in female cancer patients leads to the death of follicles in the ovary and often culminates in infertility. To preserve the fertility of women in reproductive age, prudent choice of chemo-agents and the cryopreservation of ovarian tissue before treatment can be important issues.
Cisplatin and paclitaxel are widely used in gynaecological cancer patients [1, 4], and numerous studies have been performed to elucidate their effects on ovarian function [13]. To date, their toxic effects on the ovarian reserve were demonstrated by assessing the damage to ovarian tissue and diminished residual follicles, via experiments using ovarian tissue or whole ovaries [14, 15]. Recent in vitro studies using ovarian tissue culture found that, in a dose-dependent manner, taxane drugs caused the primary follicle depletion and that granulosa cells were the first cells to be affected [16].
To establish the strategy for fertility preservation, it is important to evaluate the chemo-drugs’ effects on developing follicles [11]. The cells of developing follicles are proliferating actively, and they can be targets of chemo-agents [17]. It may be expected that chemo-drugs affect the G-cells more signifiacntly than non-dividing oocytes. And chemo-reagents could affect developing stages of pre-antral and antral follicles more negatively (Figure 1).
Evidence from a previous report suggested that the treatment of taxanes can induce apoptosis [18], while another study showed that taxanes only had minimally toxic effects on the ovarian function [19]. In other previous studies, paclitaxel treatment suppressed follicle growth and antral formation [20].
Taxanes are usually administered in combination with other chemotherapeutic agents, and, in this case, their own toxic effects against ovarian function are difficult to determine [21, 22]. Paclitaxel is known to delay oocyte maturation and to induce oocytes aneuploidy [23]. Other in vivo studies using high-dose paclitaxel showed that paclitaxel treatment induced primordial follicle loss [24, 25]. A previous report on the treatment of paclitaxel showed the increased apoptosis of G-cells in developing follicles [20]. It seems that paclitaxel is more toxic to earlier stage follicles in vitro and in vivo [26]. However, the analyses of their effects on developing follicles is still inadequate due to ethical limitations, restricted supply of human follicles, and the absence of suitable models of the in vitro follicular maturation system. Bcl-2 acts as an anti-apoptotic regulator, and this gene is expressed in mammalian oocytes and G-cells [27]. In the mammalian ovary, the levels of anti-apoptotic and pro-apoptotic gene expression are known to be low in healthy follicles and increased in atretic follicles [28, 29].
The expression of all tested genes was down-regulated, and the affected degree differed among the treated groups. AMH and GDF9 demonstrated higher expression in the paclitaxel-treated group (Figure 4). GDF-9, expressed in oocytes, is known to be a paracrine regulator of growth and differentiator of ovarian somatic cells [30]. The relatively high expression of GDF-9 in the present study may have been caused by the generation of reactive oxygen species (ROS) disrupting the membrane when paclitaxel is treated [31]. In the present study, combined treatment significantly increased the apoptosis of growing follicles, and the expression of Bcl-2 was decreased. These results are correlated with expression of XIAP, another anti-apoptotic factor related to the development of follicles. XIAP, a known inhibitor of apoptosis protein 3 (IAP3), is a protein that stops apoptotic cell death. XIAP is expressed in all the stages of follicle development and promotes survival of follicles by inhibiting caspase-3, -7, and -9 [32, 33]. Overexpression of XIAP significantly enhances the survival of pre-antral follicles, and thus XIAP could be used as a pre- and post-chemo protective agent due to its distinct role in regulating follicle atresia.
The regulation of follicle atresia is an important issue in fertility preservation. Currently, a number of strategies including gonadotropin-releasing hormone (GnRH) agonist are used for the protection of ovarian reserve [34]. It interferes with the hypothalamic-pituitary-gonadal axis and blocks ovarian function by suppressing gonadotropin levels to pubertal levels. However, its effect is not satisfactory for the preservation of ovarian function [35]. Therefore, the pre- and post-chemo rescuing of follicles using XIAP could be a candidate strategy for maintaining ovarian reserve.
In conclusion, we demonstrated the effects of cisplatin and paclitaxel on in vitro follicular growth. Their effects were differentially observed between oocytes and G-cells regarding the gene expression and morphological variation. Further investigations are necessary to evaluate the potential efficacy of XIAP as an anti-apoptotic regulator when used before chemotherapy. The potential use of stem cells extracted from ovaries should also be evaluated in regard to their supportive roles during in vitro murine and primate follicle culture setting of this study.

Acknowledgments

Yoon Young Kim and Woo Oh Kim equally contributed to this work.
The authors would like to state their appreciation for the sincere technical and statistical assistance of Kyung Mee Cho, Hye Jun Min, Mi Ae Lee, and Da Young Song.
This study was supported by grants of the Ministry of Science, ICT and Future Planning (2016R1E1A1A01943455), the Korean Health Tech­nology R&D Project, the Ministry of Health & Welfare (HI14C2289), and Seoul National University Hospital Research Fund (0420160930).

Conflict of interest

The authors declare no conflict of interest.

References

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Eppig JJ, O’Brien MJ. Development in vitro of mouse oocytes from primordial follicles. Biol Reprod 1996; 54: 197-207.
3. Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem 2015; 6: 231-9.
4. Rowinsky EK. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 1994; 28 (5 Suppl.): S18-22.
5. Fabbri R. Cryopreservation of human oocytes and ovarian tissue. Cell Tissue Bank 2006; 7: 113-22.
6. Kim YJ, Ku SY, Kim YY, et al. MicroRNAs transfected into granulosa cells may regulate oocyte meiotic competence during in vitro maturation of mouse follicles. Hum Reprod 2013; 28: 3050-61.
7. Park KE, Ku SY, Jung KC, et al. Effects of urinary and recombinant gonadotropins on in vitro maturation outcomes of mouse preantral follicles. Reprod Sci 2013; 20: 909-16.
8. Kim YJ, Ku SY, Rosenwaks Z, et al. MicroRNA expression profiles are altered by gonadotropins and vitamin C status during in vitro follicular growth. Reprod Sci 2010; 17: 1081-9.
9. Kim YY, Yun JW, Kim JM, et al. Gonadotropin ratio affects the in vitro growth of rhesus ovarian preantral follicles. J Investig Med 2016; 64: 888-93.
10. Yun JW, Kim YY, Ahn JH, et al. Use of nonhuman primates for the development of bioengineered female reproductive organs. Tissue Eng Regen Med 2016; 13: 323-34.
11. Lopes F, Smith R, Anderson RA, Spears N. Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles. Mol Hum Reprod 2014; 20: 948-59.
12. Kim YJ, Kim YY, Kang BC, et al. Induction of multiple ovulation via modulation of angiotensin II receptors in in vitro ovarian follicle culture models. J Tissue Eng Regener Med 2016; DOI: https://doi.org/10.1002/term.2214.
13. Donnez J, Dolmans MM. Fertility preservation in women. Nat Rev Endocrinol 2013; 9: 735-49.
14. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7: 535-43.
15. Meirow D, Hardan I, Dor J, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod 2008; 23: 1007-13.
16. Vanacker J, Luyckx V, Amorim C, et al. Should we isolate human preantral follicles before or after cryopreservation of ovarian tissue? Fertil Steril 2013; 99: 1363-8e2.
17. Morgan S, Lopes F, Gourley C, Anderson RA, Spears N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PloS One 2013; 8: e70117.
18. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007; 30: 126-32.
19. Fornier M, Hudis C. Adjuvant chemotherapy for primary breast cancer. Curr Oncol Rep 2005; 7: 18-22.
20. Tarumi W, Suzuki N, Takahashi N, et al. Ovarian toxicity of paclitaxel and effect on fertility in the rat. J Obstet Gynaecol Res 2009; 35: 414-20.
21. Perez-Fidalgo JA, Rosello S, Garcia-Garre E, et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat 2010; 120: 245-51.
22. Torino F, Paragliola RM, Barnabei A, Corsello SM. Medullary thyroid cancer: a promising model for targeted therapy. Curr Mol Med 2010; 10: 608-25.
23. Mailhes JB, Carabatsos MJ, Young D, London SN, Bell M, Albertini DF. Taxol-induced meiotic maturation delay, spindle defects, and aneuploidy in mouse oocytes and zygotes. Mutat Res 1999; 423: 79-90.
24. Gucer F, Balkanli-Kaplan P, Doganay L, et al. Effect of paclitaxel on primordial follicular reserve in mice. Fertil Steril 2001; 76: 628-9.
25. Yucebilgin MS, Terek MC, Ozsaran A, et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol 2004; 44: 6-9.
26. Kim YY, Ku JB, Liu HC, Ku SY, Kim SH, Choi YM. Ginsenosides may enhance the functionality of human embryonic stem cell-derived cardiomyocytes in vitro. Reprod Sci 2014; 21: 1312-8.
27. De Bem TH, Adona PR, Bressan FF, et al. The influence of morphology, follicle size and Bcl-2 and Bax transcripts on the developmental competence of bovine oocytes. Reprod Domest Anim 2014; 49: 576-83.
28. Kim MR, Tilly JL. Current concepts in Bcl-2 family member regulation of female germ cell development and survival. Biochim Biophys Acta 2004; 1644: 205-10.
29. Kim YY, Tamadon A, Ku SY. Potential use of antiapoptotic proteins and noncoding rnas for efficient in vitro follicular maturation and ovarian bioengineering. Tissue Eng Part B Rev 2017; 23: 142-58.
30. Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 1996; 383: 531-5.
31. Su TR, Tsai FJ, Lin JJ, et al. Induction of apoptosis by 11-dehydrosinulariolide via mitochondrial dysregulation and ER stress pathways in human melanoma cells. Marine Drugs 2012; 10: 1883-98.
32. Li J, Kim JM, Liston P, et al. Expression of inhibitor of apoptosis proteins (IAPs) in rat granulosa cells during ovarian follicular development and atresia. Endocrinology 1998; 139: 1321-8.
33. Ene AC, Park S, Edelmann W, Taketo T. Caspase 9 is constitutively activated in mouse oocytes and plays a key role in oocyte elimination during meiotic prophase progression. Dev Biol 2013; 377: 213-23.
34. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011; 95: 906-14e1-4.
35. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013; 121: 78-86.
Copyright: © 2019 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe